Hyperfine Q2 revenue $2.7M (+26% QoQ), net loss $9.2M; FDA clearances for Optive AI and next-gen Swoop

Hyperfine, Inc.

2025-Q2 EPS reported -$0.24 vs consensus -$0.12 ▼ miss (-96.1%)

Revenue $2.7M, up 26% from Q1; sold 8 commercial Swoop systems vs 6 in Q1.
Net loss $9.2M ($0.12/share) vs $9.4M in Q1; gross margin 49.3%, up 800 bps QoQ.
FDA cleared Optive AI software and next-generation Swoop system; commercial rollout begun.
Completed neurology office pilot; full-scale commercial launch initiated.
FY 2025 revenue guidance: 10-20% over 2024; cash burn guided to $27-29M, down 27% YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.